Table 3.
Comorbidities of patients of the included studies.
| Study | Diabetes n (%) |
Hypertensionn (%) |
Cardiovascular disease n (%) |
Respiratory disease n (%) |
Malignancy n (%) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Critical/Mortal | Non-critical | Critical/Mortal | Non-critical | Critical/Mortal | Non-critical | Critical/Mortal | Non-critical | Critical | Non-critical | |
| Guan WJ | 67 (26.9%) | 63 (6.1%) | 24 (35.8%) | 141 (13.7%) | 6 (9.0%) | 21 (2.0%) | 7 (10.4%) | 5 (0.5%) | 1 (1.5%) | 9 (0.9%) |
| Huang C | 13 (7.7%) | 7 (25.0%) | 2 (15.4%) | 4 (14.3%) | 3 (23.1%) | 3 (10.7%) | 1 (7.7%) | 0 | 0 | 1 (3.6%) |
| Mo P | 85 (14.1%) | 3 (4.3%) | 22 (25.9%) | 15 (21.4%) | 14 (16.5%) | 0 | 4 (4.7%) | 0 | 5 (5.9%) | 2 (2.9%) |
| Peng YD | 16 (25.0%) | 19 (19.8%) | 10 (62.5%) | 82 (85.4%) | — | — | — | — | — | — |
| Shi Y | 49 (14.3%) | 22 (5.0%) | 26 (53.1%) | 73 (16.7%) | 4 (8.2%) | 7 (1.6%) | — | — | 2 (4.1%) | 3 (0.7%) |
| Wang D | 36 (22.2%) | 6 (5.9%) | 21 (58.3%) | 22 (21.6%) | 9 (25.0%) | 11 (10.8%) | 3 (8.3%) | 1 (1.0%) | 4 (11.1%) | 6 (5.9%) |
| Wang Z | 14 (42.9%) | 1 (1.8%) | 5 (35.7%) | 4 (7.3%) | 5 (35.7%) | 3 (5.5%) | 2 (14.3%) | 4 (7.3%) | 1 (7.1%) | 3 (5.5%) |
| Wu C | 84 (19.0%) | 6 (5.1%) | 23 (27.4%) | 16 (13.7%) | 5 (6.0%) | 3 (2.6%) | — | — | — | — |
| Yang X | 32 (21.9%) | 2 (10.0%) | — | — | 3 (9.4%) | 2 (10.0%) | 2 (6.3%) | 2 (10.0%) | 1 (3.1%) | 1 (5.0%) |
| Yuan ML | 10 (60.0%) | 0 | 5 (50.0%) | 0 | 3 (30.0%) | 0 | — | — | 0 | 1 (5.9%) |
| Zhou F | 54 (31.5%) | 19 (12.9%) | 26 (48.1%) | 32 (21.8%) | 13 (24.1%) | 2 (1.4%) | 4 (7.4%) | 2 (1.4%) | 0 | 2 (1.4%) |